These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22383181)

  • 1. Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension.
    Correale M; Montrone D; Biase MD; Brunetti ND
    Clin Res Cardiol; 2012 Jul; 101(7):593-4. PubMed ID: 22383181
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Ivabradine on Heart Rate and Duration of Exercise in Patients With Mild-to-Moderate Mitral Stenosis: A Randomized Comparison With Metoprolol.
    Saggu DK; Narain VS; Dwivedi SK; Sethi R; Chandra S; Puri A; Saran RK
    J Cardiovasc Pharmacol; 2015 Jun; 65(6):552-4. PubMed ID: 25636072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?
    Correale M; Montrone D; Ieva R; Di Biase M; Brunetti ND
    Clin Res Cardiol; 2013 May; 102(5):391-3. PubMed ID: 23389056
    [No Abstract]   [Full Text] [Related]  

  • 4. A paradigm shift in pulmonary arterial hypertension management.
    Rubin LJ; Galiè N; Simonneau G; McLaughlin V
    Eur Respir Rev; 2013 Dec; 22(130):423-6. PubMed ID: 24293459
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic Sclerosis and Pulmonary Hypertension: The Great Masquerader.
    Baratto C; Caravita S; Battista Perego G; Badano LP; Vachiéry JL; Parati G
    Circ Heart Fail; 2021 Feb; 14(2):e007554. PubMed ID: 33504158
    [No Abstract]   [Full Text] [Related]  

  • 6. Ivabradine in systemic sclerosis related pulmonary arterial hypertension.
    Correale M; Montrone D; Ieva R; Di Biase M; Brunetti ND
    Eur J Intern Med; 2012 Dec; 23(8):e210-1. PubMed ID: 23021874
    [No Abstract]   [Full Text] [Related]  

  • 7. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
    Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW
    Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis].
    Volkov AV; Kurmukov IA; Yudkina NN; Glukhova SI; Nikolaeva EV
    Ter Arkh; 2015; 87(1):49-56. PubMed ID: 25823269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angina: Ivabradine for treatment of stable angina pectoris.
    de Silva R; Fox KM
    Nat Rev Cardiol; 2009 May; 6(5):329-30. PubMed ID: 19377492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of ivabradine on pulmonary hypertension in chronic obstructive pulmonary disease].
    Akhmetzianova ÉKh; Gaĭnitdinova VV; Bakirov AB; Bogoroditskaia OA; Timershina IR
    Kardiologiia; 2012; 52(2):41-6. PubMed ID: 22792738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic Response to Oral Vasodilator Therapy in Systemic Sclerosis-Related Pulmonary Hypertension.
    Lui JK; Sangani RA; Gillmeyer KR; Vakhshoorzadeh J; Trojanowski MA; Bujor AM; Gopal DM; Wiener RS; LaValley MP; Klings ES
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):651-656. PubMed ID: 36607535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary hypertension: a correct diagnosis for a suitable therapy in scleroderma patients.
    Giordano N; Montella A; Corallo C; Ruocco G; Chirico C; Palazzuoli A; Nuti R; Pecetti G
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S182-9. PubMed ID: 26339897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent but Preventable Pulseless Electrical Activity Arrest: Follow the Guidelines!
    El Hajj MC; Cai AW; Houston BA; Tedford RJ
    Circ Heart Fail; 2020 Mar; 13(3):e006781. PubMed ID: 32156168
    [No Abstract]   [Full Text] [Related]  

  • 14. Six-minute walk test in scleroderma-associated pulmonary arterial hypertension: are we counting what counts?
    Pamidi S; Mehta S
    J Rheumatol; 2009 Feb; 36(2):216-8. PubMed ID: 19208554
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.
    Kylhammar D; Persson L; Hesselstrand R; Rådegran G
    Scand Cardiovasc J; 2014 Aug; 48(4):223-33. PubMed ID: 24912571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension.
    Strange C; Bolster M; Mazur J; Taylor M; Gossage JR; Silver R
    Chest; 2000 Oct; 118(4):1077-82. PubMed ID: 11035680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bosentan improves functional class, pulmonary artery systolic pressure, and DLCO in scleroderma patients with pulmonary hypertension: a possible synergy with iloprost.
    Beretta L; Scorza R; Del Papa N; Mazzone A
    J Rheumatol; 2006 Sep; 33(9):1915-6; author reply 1916. PubMed ID: 16960959
    [No Abstract]   [Full Text] [Related]  

  • 18. Exercise-induced pulmonary hypertension in systemic sclerosis: a multifactorial entity.
    Baptista R; Teixeira R
    Am Heart J; 2013 Sep; 166(3):e13. PubMed ID: 24016514
    [No Abstract]   [Full Text] [Related]  

  • 19. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of ivabradine in patients with stable angina and comorbid chronic obstructive pulmonary disease].
    Khamaeva AA; Belialov FI; Kerzina LV; Berezovskaia OV; Parshukova ED; Zakharova GIu
    Kardiologiia; 2012; 52(1):15-9. PubMed ID: 22304347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.